GU Cancers 2019 | CheckMate 214 trial in RCC updates

David McDermott

Prof. David McDermott, MD, of Beth Israel Deaconess Medical Center, Boston, MA, discusses results from the Phase III Checkmate 214 trial, which brought PD1 blockers into the frontline of renal cell carcinoma (RCC) treatment. Prof. McDermott explained that nivolumab administration in combination with ipilimumab improved previously untreated RCC overall survival, when compared with sunitinib. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video